Home | Investors | ASX Announcements | 2017 ASX Announcements 2017 Date Document 20/12/2017 Customer Newsletter - December 2017 15/12/2017 Multi Centre testing commences for AI solution 11/12/2017 Change of Director's Interest Notice 01/12/2017 Appendix 3Y Change of Director's Interest Notice 30/11/2017 Company Secretary Appointment/Resignation 23/11/2017 Results of Meeting 20/11/2017 Change Substantial Shareholder Notification 20/11/2017 Appendix 3Y Change of Director's Interest Notice 31/10/2017 Appendix 4C - quarterly 23/10/2017 Annual Report to shareholders 19/10/2017 Investor Presentation 17/10/2017 Notice of General Meeting/Proxy Form 17/10/2017 Collaborative Partnership to develop new AI Diagnostic tools 17/10/2017 Beta Testing Success for Cloud-Based A.I. Prototype 02/10/2017 Customer Newsletter 28/09/2017 Appendix 4G and Corporate Governance Statement 28/09/2017 Annual Report 2017 30/08/2017 Preliminary Final Report 21/08/2017 Beta Testing Commences for Cloud-Based A.I Prototype 31/07/2017 Appendix 4C - quarterly 17/07/2017 Equity Research Update Report Released 05/07/2017 New Registered Office and Business Address 03/07/2017 Final Director's Interest Notice 30/06/2017 Customer Newsletter - June 2017 29/06/2017 Resignation of Non-Executive Director 22/06/2017 Bone Marrow Iron Assessment Launch 21/06/2017 Leading Patient NGO Endorses FerriScan and AI Technology 14/06/2017 Artificial Intelligence Solution for Emerging Markets 28/04/2017 Quarterly Report 18/04/2017 FerriScan not impacted by Fatty Liver 12/04/2017 Evidence Building for HepaFat-Scan 05/04/2017 Appendix 3Y Panton 30/03/2017 Customer Newsletter - March 2017 23/03/2017 Cancer Survivor Campaign Update 01/03/2017 Updated Securities Trading Policy 28/02/2017 Half year report 09/02/2017 Change in substantial holding 31/01/2017 Appendix 4C - quarterly 12/01/2017 Maylasian NAFLD - Diabetes Study